Skip to main content

Tarsus Pharmaceuticals, Inc. (TARS)

NASDAQ: TARS · IEX Real-Time Price · USD
27.46 -0.07 (-0.25%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap570.73M
Revenue (ttm)55.45M
Net Income (ttm)-4.88M
Shares Out20.56M
EPS (ttm)-0.33
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume26,929
Open27.74
Previous Close27.53
Day's Range26.48 - 27.95
52-Week Range17.96 - 63.69
Betan/a
AnalystsStrong Buy
Price Target56.80 (+106.8%)
Est. Earnings DateNov 3, 2021

About TARS

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was ...

IndustryBiotechnology
IPO DateOct 16, 2020
Employees20
Stock ExchangeNASDAQ
Ticker SymbolTARS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price forecast is 56.80, which is an increase of 106.85% from the latest price.

Price Target
$56.80
(106.85% upside)
Analyst Consensus: Strong Buy

News

Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Dir...

Ms. Crane brings over 30 years of experience in executive leadership, commercialization, and business development in the pharmaceutical and healthcare industries

2 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates

Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis; results presented at the 2021 American Society of Cataract and Refractive Surgery (ASC...

2 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results a...

New Saturn-1 data demonstrated a strong patient responder rate with 95% of Demodex blepharitis patients treated with TP-03 achieving ≤0.5 mites per lash and 93% improving by at least one collarette grade

2 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference

IRVINE, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven s...

3 months ago - GlobeNewsWire

3 Top Biotech Stocks to Buy Right Now

These three biotech stocks recently had positive news coming out of phase 2 trials, making them good choices for growth-oriented investors.

Other symbols:AVXLMNOV
3 months ago - The Motley Fool

Tarsus Pharmaceuticals, Inc. to Participate in the Raymond James 2021 Human Health Innovation Conference

IRVINE, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven s...

4 months ago - GlobeNewsWire

Tarsus Pharmaceuticals' TP-03 Hits Primary, Secondary Endpoints In Demodex Blepharitis Study

Tarsus Pharmaceuticals Inc (NASDAQ: TARS) has reported topline data from Phase 2b/3 Saturn-1 trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) in patients with Demodex blepharitis.  81% of p...

4 months ago - Benzinga

Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment ...

Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-related adverse events and no treatment-related ...

4 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Resu...

IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven s...

4 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for th...

More than 30 million Americans at risk for Lyme disease exposure, which can result in severe neurological and other debilitating symptoms

4 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual Healthcare Conference

IRVINE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven sc...

4 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates

Initiated Saturn-2, second pivotal Phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis; topline data from Saturn-1 expected this July

5 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Dise...

Novel candidate in development aims to be first approved non-vaccine therapeutic for Lyme disease prevention

5 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the...

Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans

5 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference

IRVINE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven ...

5 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates

Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021

6 months ago - GlobeNewsWire

Tarsus Pharma Partners With LianBio For TP-03 In Greater China For Eye Diseases

Tarsus Pharmaceuticals Inc (NASDAQ: TARS) and LianBio have announced a strategic partnership to develop and commercialize TP-03 in Greater China (mainland China, Hong Kong, Taiwan, and Macau). TP-03 (lo...

6 months ago - Benzinga

Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China...

Deal expands access to TP-03 for approximately 40 million patients with Demodex blepharitis and 70 million patients with Meibomian Gland Disease in China, the world's second largest healthcare market De...

6 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel

IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treat...

9 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. Appoints Dianne Whitfield as Chief Human Resources Officer

IRVINE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treat...

9 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. to Present at the 2021 ICR Virtual Conference

IRVINE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treat...

9 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. Announces Type C Meeting with FDA Regarding NDA Submission Requirements for Lead Candida...

The Company began enrolling patients in Saturn-1 in September 2020 and expects to initiate its second pivotal registration trial, Saturn-2, in 2021 The Company began enrolling patients in Saturn-1 in Se...

9 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. Announces Inclusion in the Russell 3000® Index and Russell 2000® Index

IRVINE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treat...

10 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. Appoints Wendy Yarno to Board of Directors

IRVINE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treat...

11 months ago - GlobeNewsWire

Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare Conference

IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus” NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthro...

11 months ago - GlobeNewsWire